Related Experiment Video
Updated: Jun 12, 2026
07:16
Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
Fragrant dioxane derivatives identify beta1-subunit-containing GABAA receptors
Olga A Sergeeva1, Olaf Kletke, Andrea Kragler
1Lehrstuhl für Zellphysiologie, Ruhr-Universität, 44780 Bochum, Germany. olga.sergeeva@uni-duesseldorf.de
The Journal of Biological Chemistry
|June 1, 2010
Summary
Researchers discovered new GABA(A) receptor modulators, fragrant dioxane derivatives (FDDs), that selectively target beta1-subunits. This finding reveals the functional role of beta1-containing GABA(A) receptors in the hypothalamus and provides a new research tool.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Mammals possess nineteen known GABA(A) receptor (GABA(A)R) subunits, but the functional roles of many native combinations remain unclear.
- The specific physiological function of GABA(A)Rs containing the beta1-subunit has not been previously identified.
Purpose of the Study:
- To identify novel positive modulators of GABA(A) receptors with selectivity for the beta1-subunit.
- To investigate the role of beta1-subunit-containing GABA(A)Rs in neuronal function, particularly in wakefulness control.
Main Methods:
- Discovery and characterization of a new class of GABA(A)R modulators: fragrant dioxane derivatives (FDDs).
- Electrophysiological recordings (whole-cell responses, synaptic currents) in heterologously expressed GABA(A)Rs and native neurons.
- Site-directed mutagenesis of key amino acid residues in beta1 and beta3 subunits.
- siRNA-mediated knockdown of the beta1-subunit in cultured hypothalamic neurons.
Main Results:
- Fragrant dioxane derivatives (FDDs) demonstrated significantly higher potency (6-fold) for beta1-subunit-containing GABA(A)Rs compared to beta2- and beta3-containing receptors.
- Specific amino acid residues (Serine at position 265 and the mutation beta1N286W) in the beta1-subunit were critical for FDD sensitivity, with reciprocal mutations in the beta3-subunit mimicking beta1-type sensitivity.
- FDDs potently modulated GABA-mediated responses in posterior hypothalamic neurons, which control wakefulness, but not in beta1-negative cerebellar Purkinje neurons.
- siRNA treatment targeting the beta1-subunit reduced both beta1-subunit immunostaining and FDD potency in cultured hypothalamic neurons.
Conclusions:
- Fragrant dioxane derivatives (FDDs) represent a novel class of positive allosteric modulators with distinct beta1-subunit selectivity for GABA(A) receptors.
- The study provides the first evidence for the functional expression of beta1-subunit-containing GABA(A)Rs in posterior hypothalamic neurons, implicating them in the regulation of wakefulness.
- FDDs serve as valuable pharmacological tools for dissecting the functional diversity of native GABA(A)Rs and exploring their roles in the central nervous system.
Related Concept Videos
01:30Transducer Mechanism: G Protein–Coupled Receptors
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical, 7TM, or...
GPCRs are also called heptahelical, 7TM, or...
01:17Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...
01:26Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
01:16Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
01:31Adrenergic Receptors: ɑ Subtype
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...